新辅助化疗联合区域热疗对局部高危软组织肉瘤长期结局的影响:EORTC 62961-ESHO 95随机临床试验
该开放标签3期随机试验纳入341例局部高危软组织肉瘤患者,比较新辅助化疗联合区域热疗与单纯化疗的疗效。
要点
- 新辅助化疗联合区域热疗可改善局部高危软组织肉瘤的局部无进展生存期。
- 联合区域热疗组总生存期显著优于单纯化疗组,5年生存率62.7% vs 51.3%。
- 对于适合新辅助治疗的患者,加用区域热疗可能值得考虑。
核心结论
- 在局部高危软组织肉瘤患者中,新辅助化疗联合区域热疗较单纯化疗提高了总生存率和局部无进展生存期。
研究设计与样本
- 开放标签、3期随机临床试验,1997年7月至2006年11月从9个中心(德国6个、挪威1个、奥地利1个、美国1个)纳入341例成人局部软组织肉瘤患者,329例符合意向性治疗分析。
关键数值与推荐
- 入组标准:年龄≥18岁,局部软组织肉瘤(肿瘤≥5 cm,FNCLCC分级2或3级,深部)。
- 随机分组前按肿瘤表现和部位进行分层。
- 主要终点为局部无进展生存期,次要终点包括治疗安全性和生存。
临床怎么用
- 对于适合新辅助治疗的局部高危软组织肉瘤患者,可考虑在新辅助化疗基础上加用区域热疗以改善生存。
局限性
- 开放标签设计可能引入偏倚。
- 研究纳入时间较早(1997-2006年),后续治疗模式可能已变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with soft tissue sarcoma are at risk for local recurrence and distant metastases despite optimal local treatment. Preoperative anthracycline plus ifosfamide chemotherapy improves outcome in common histological subtypes. OBJECTIVE: To analyze whether the previously reported improvement in local progression-free survival by adding regional hyperthermia to neoadjuvant chemotherapy translates into improved survival. DESIGN, SETTING, AND PARTICIPANTS: Open-label, phase 3 randomized clinical trial to evaluate the efficacy and toxic effects of neoadjuvant chemotherapy plus regional hyperthermia. Adult patients (age ≥18 years) with localized soft tissue sarcoma (tumor ≥5 cm, French Federation Nationale des Centers de Lutte Contre le Cancer [FNCLCC] grade 2 or 3, deep) were accrued across 9 centers (6, Germany; 1, Norway; 1, Austria; 1, United States) from July 1997 to November 2006. Follow-up ended December 2014. INTERVENTIONS: After stratification for tumor presentation and site, patients were randomly assigned to either neoadjuvant chemotherapy consisting of doxorubicin, ifosfamide, and etoposide alone, or combined with regional hyperthermia. MAIN OUTCOMES AND MEASURES: The primary end point was local progression-free survival. Secondary end points included treatment safety and survival, with survival defined from date of randomization to death due to disease or treatment. Patients lost to follow-up were censored at the date of their last follow-up. RESULTS: A total of 341 patients were randomized, and 329 (median [range] age, 51 [18-70] years; 147 women, 182 men) were eligible for the intention-to-treat analysis. By December 2014, 220 patients (67%; 95% CI, 62%-72%) had experienced disease relapse, and 188 (57%; 95% CI, 52%-62%) had died. Median follow-up was 11.3 years. Compared with neoadjuvant chemotherapy alone, adding regional hyperthermia improved local progression-free survival (hazard ratio [HR], 0.65; 95% CI, 0.49-0.86; P = .002). Patients randomized to chemotherapy plus hyperthermia had prolonged survival rates compared with those randomized to neoadjuvant chemotherapy alone (HR, 0.73; 95% CI, 0.54-0.98; P = .04) with 5-year survival of 62.7% (95% CI, 55.2%-70.1%) vs 51.3% (95% CI, 43.7%-59.0%), respectively, and 10-year survival of 52.6% (95% CI, 44.7%-60.6%) vs 42.7% (95% CI, 35.0%-50.4%). CONCLUSIONS AND RELEVANCE: Among patients with localized high-risk soft tissue sarcoma the addition of regional hyperthermia to neoadjuvant chemotherapy resulted in increased survival, as well as local progression-free survival. For patients who are candidates for neoadjuvant treatment, adding regional hyperthermia may be warranted. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00003052.
引用
- Issels RD, Lindner LH, Verweij J, et al. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29450452. doi:10.1001/jamaoncol.2017.4996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。